Paper Details

  1. Home
  2. Paper Details

GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.

Author: BeamSandra L, BrownSally D, EliasE George, ZapasJohn L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the combined use of GM-CSF and IL-2, two cytokines, as adjuvant therapy for high-risk melanoma patients after surgery. The combination therapy was well-tolerated and showed promising results, suggesting further clinical evaluation is warranted.
Paper Details　
Original Abstract of the Article :
Cytokines have been used in the treatment of patients with cutaneous melanoma. Granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]) leads to dendritic cell/macrophage priming and activation, and also increases interleukin-2 (IL-2) receptor expression on T. lymphocytes. I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15934495

データ提供：米国国立医学図書館（NLM）

A Combined Force Against Melanoma: GM-CSF and IL-2

Cutaneous melanoma, a type of skin cancer, can be aggressive and difficult to treat. This study explores the potential of combining two cytokines, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2), as an adjuvant therapy for high-risk melanoma patients. The authors investigated the safety and efficacy of this combination therapy in a clinical trial, finding that it was well tolerated and showed promising early results in reducing the risk of melanoma recurrence.

A Promising Alliance: GM-CSF and IL-2 for Melanoma Treatment

The combination of GM-CSF and IL-2 appears to be a safe and potentially effective adjuvant therapy for high-risk melanoma patients. This study provides strong evidence for further clinical investigation of this promising regimen. The study also highlights the potential of harnessing the power of the immune system to fight cancer.

Protecting Your Skin: A Combined Force Against Melanoma

Melanoma is a serious threat, but this research offers hope for new and effective treatments. While this study is promising, more research is needed to confirm the long-term efficacy of this combination therapy. Remember, regular skin checks are crucial for early detection and prevention of melanoma.

Dr. Camel's Conclusion

This research, like a desert bloom, provides a ray of hope in the fight against melanoma. The combination of GM-CSF and IL-2 offers a potentially powerful weapon in our arsenal against this aggressive cancer, and further research holds promise for improved treatment outcomes.

Date :
  1. Date Completed 2005-08-16
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

15934495

DOI: Digital Object Identifier

163996

Related Literature

Article Analysis
・Side Effects of sargramostim
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.